CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 12, p. 3701, doi. 10.1007/s00262-021-03008-0

By:

• Reusing, Sarah B.;
• Vallera, Dan A.;
• Manser, Angela R.;
• Vatrin, Titus;
• Bhatia, Sanil;
• Felices, Martin;
• Miller, Jeffrey S.;
• Uhrberg, Markus;
• Babor, Florian

Publication type:

Article